Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network

Nathalie Muls; Karima Jnaoui; Hong Anh Dang; Antony Wauters; Jacques Van Snick; Christian Jean-Marie Sindic; Vincent van Pesch

doi:10.1016/j.jneuroim.2011.12.010

Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network

J Neuroimmunol. 2012 Feb 29;243(1-2):73-80. doi: 10.1016/j.jneuroim.2011.12.010. Epub 2012 Jan 14.

Authors

Nathalie Muls¹, Karima Jnaoui, Hong Anh Dang, Antony Wauters, Jacques Van Snick, Christian Jean-Marie Sindic, Vincent van Pesch

Affiliation

¹ Unité de Neurochimie, Institute of Neuroscience, Avenue Mounier, 53 (BP 53.02), Belgium.

PMID: 22245284
DOI: 10.1016/j.jneuroim.2011.12.010

Abstract

The concomitant production of IL-17A and IL-9, both Th17 cytokines, has not been compared in MS patients. We show that IL-17A but not IL-9 expression by CD3(+) cells was increased during a MS relapse. Co-expression of IL-17A and IL-9 was marginal. In addition to Th1 and Th2 cytokines, IL-17A, IL-6 and IL-23p19 were down-regulated by ivMP, but Foxp3 was not, while an increase in IL-10, TGF-β1 and IL-27p28 mRNA was observed. This change in the Th17, Treg and IL-10 balance could be an additional mechanism by which corticosteroids shorten the duration of a MS relapse and promote recovery.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adrenal Cortex Hormones / pharmacology*
Analysis of Variance
Blood Cells / drug effects*
Cytokines / genetics
Cytokines / metabolism
Demyelinating Diseases / pathology*
Enzyme-Linked Immunosorbent Assay
Flow Cytometry
Humans
Interleukin-17 / genetics
Interleukin-17 / metabolism*
Interleukin-9 / genetics
Interleukin-9 / metabolism*
Multiple Sclerosis / pathology*
Up-Regulation / drug effects*

Substances

Adrenal Cortex Hormones
Cytokines
Interleukin-17
Interleukin-9